Results and discussion Computation-aided identification of ncAA incorporation site Two high-affinity anti-PD-L1 nanobodies, PV2 and PV3, sharing a sequence identity of 86.5%, were selected for constructing bispecific nanobodies (BsNbs) for CRC treatment (Fig
Tirzepatide and Semaglutide are two innovative medications that have gained significant attention in the realm of weight loss treatment
They enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite via central hypothalamic pathways, leading to lower energy intake and improved glycemic control
Superoxide anion, in turn, serves to generate other reactive oxygen species (ROS) that kill the phagocytosed microorganisms
When consolidating the two GF mouse cohorts, only those receiving intraperitoneal saline before the OFT (Fig